Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...

Lantus – said to be the most administered basal insulin across the world – continues to make blockbuster sales, bringing in almost $775 million for Sanofi in the first quarter of this year.

It sells products through independent distributors primarily in India.Sanofi Indias products viz. Lantus, Combiflam, Amaryl and Allegra feature in the top 100 pharmaceutical brands in India.

On average, insulin glargine biosimilars achieve a 26% market share after 5 years on the market. 3 Sanofi's dual pricing strategy may have slowed the market uptake of insulin biosimilars ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Sanofi (NASDAQ:SNY) disclosed a free cash flow of €6 billion in 2024, which was brought down by slashed prices of Lantus in H1 in the US, eliminating receivables, and unfavorable exchange rate ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

Sanofi’s MERILOG™ is now the first insulin aspart biosimilar, and the third insulin biosimilar product to be approved by the FDA, behind Biocon’s SEMGLEE® (insulin glargine-yfgn ...

These dynamics have led to branded insulin products and generic versions from branded players (like Lilly's Basaglar, a generic version of Sanofi's Lantus) retaining most of the insulin market.